What is Monte Rosa Therapeutics, Inc.'s net income?

Monte Rosa Therapeutics, Inc. (GLUE) reported net income of -$44.5M in Q1 2026.

How has Monte Rosa Therapeutics, Inc.'s net income changed year-over-year?

Monte Rosa Therapeutics, Inc.'s net income decreased by 194.9% year-over-year, from $46.89M to -$44.5M.

What is the long-term trend for Monte Rosa Therapeutics, Inc.'s net income?

Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s net income has grown at a -19.5% compound annual growth rate (CAGR), from -$73.96M to -$38.63M.

What does net income mean?

Net income as the starting point for the indirect method operating cash flow reconciliation.

Monte Rosa Therapeutics, Inc. GLUE Net Income

Net Income at other companies

Bristol-Myers SquibbBMY

$2.68B+8.8%

Nurix Therapeutics, Inc.NRIX

-$87.17M-54.7%

Kymera TherapeuticsKYMR

-$69.23M-5.6%

ImmunomeIMNM

-$53.84M-29.3%

Cogent Biosciences, Inc.COGT

-$97.35M-35.2%

Adaptive BiotechnologiesADPT

-$20.02M+32.9%

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s net income?: Monte Rosa Therapeutics, Inc. (GLUE) reported net income of -$44.5M in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s net income changed year-over-year?: Monte Rosa Therapeutics, Inc.'s net income decreased by 194.9% year-over-year, from $46.89M to -$44.5M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s net income?: Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s net income has grown at a -19.5% compound annual growth rate (CAGR), from -$73.96M to -$38.63M.
What does net income mean?: Net income as the starting point for the indirect method operating cash flow reconciliation.